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Objective: The objective of this study was to analyze the early and late outcomes of patients who require a suprarenal aortic
cross-clamp during elective open repair of an abdominal aortic aneurysm (AAA).
Methods: Patients from 1998 to 2012 who required a suprarenal aortic cross-clamp during elective open AAA repair were
reviewed. Data abstracted included demographics and comorbidities; preoperative, perioperative, and late renal function;
late interventions related to AAA repair; and late mortality. A decrease in renal function was deﬁned as a >30% decline in
estimated glomerular ﬁltration rate (eGFR) compared with the preoperative value. Primary outcomes included renal
function, intervention-free survival, and overall survival.
Results: During the study period, 211 patients underwent open elective or urgent AAA repair; 69 required a suprarenal
cross-clamp. The mean age was 71 years, and 80% were men. The mean preoperative creatinine concentration was
1.2 mg/dL, and the mean preoperative eGFR was 66 mL/min/1.73 m2. Location of the aortic cross-clamp was
suprarenal (37), supramesenteric (21), and supraceliac (11). Perioperatively, 21 patients (30%) experienced a signiﬁcant
decrease in eGFR; four patients required hemodialysis. Six patients had full recovery of renal function by discharge.
Perioperative morbidity and mortality were 35% and 4%, respectively. At a mean follow-up of 3 years, seven patients had
an eGFR signiﬁcantly less than the preoperative value. Late interventions related to the AAA repair were required in eight
patients. Indications included wound complication (3), anastomotic aneurysm (2), incisional hernia (1), anastomotic
graft stenosis (1), and proximal aortic dilation (1). Overall 5-year intervention-free survival was 62% and overall survival
77%. Intervention-free survival was enhanced by antiplatelet use (P [ .04), whereas overall survival was decreased by
chronic obstructive pulmonary disease (P [ .003) and perioperative pneumonia (P [ .001).
Conclusions: More than a quarter of patients requiring a suprarenal cross-clamp during open AAA repair experience renal
dysfunction. Late graft-related complications are few, with preoperative and perioperative pulmonary function negatively
affecting overall patient survival. (J Vasc Surg 2014;60:893-9.)Patients with a juxtarenal or suprarenal abdominal
aortic aneurysm (AAA) represent a small percentage of all
patients with aortic aneurysms. Previous studies evaluating
open repair of juxtarenal and suprarenal AAAs show peri-
operative mortality rates that range from 1% to 12% as
well as a signiﬁcant incidence of postoperative renal
dysfunction.1-4 In particular, renal dysfunction can occur
in 15% to 40% of patients requiring a suprarenal cross-
clamp and is often the predominant morbidity.2,4-6
Fenestrated endovascular aneurysm repair (f-EVAR) is
an endovascular alternative to open juxtarenal and suprare-
nal AAA repair. Experience to date, predominantly from
Europe, has demonstrated 30-day mortality rates of <1%
to 4% and 3-year survival of up to 89%. However, early
and late renal dysfunction is a concern, with a 10% targetthe Division of Vascular Surgery and Endovascular Therapy, Keck
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25% incidence of late renal dysfunction.7-13
This report reviews our recent institutional experience
with open juxtarenal and suprarenal AAA repairs with a focus
on early and late renal dysfunction aswell as intervention-free
and overall survival. Our objective was to determine the re-
sults of these challenging repairs in the endovascular era
and to provide late-term information on renal dysfunction
and survival. Such information provides a context for future
therapeutic decisions concerning open vs endovascular ap-
proaches to juxtarenal and suprarenal AAAs.
METHODS
A retrospective review of all patients who underwent
open AAA repair at the Keck Hospital of University of
Southern California from August 1998 to June 2012 was
performed. The review was approved by the University of
Southern California Institutional Review Board. Patient
consent was not required. Only patients who required a su-
prarenal aortic cross-clamp for urgent or elective AAA
repair were included. Ruptured AAAs were excluded.
Demographics including age, race/ethnicity, sex, and
smoking status were abstracted. Comorbidities included
diabetes, hypertension, dyslipidemia, coronary artery dis-
ease, cerebrovascular disease, and chronic obstructive pul-
monary disease. Use of preoperative antiplatelet and893
Table I. Baseline characteristics and comorbidities of
patients
N ¼ 69
Age, years 71 6 8
Preoperative creatinine level, mg/dL 1.2 6 0.67
Preoperative eGFR, mL/min/1.73 m2 66 6 22
Aneurysm size, cm 6.12 6 1.5
Sex
Male 55 (79.7)
Female 14 (20.3)
Hypertension 61 (88.4)
Diabetes 15 (22.1)
Hyperlipidemia 47 (68.2)
Statin 52 (75.4)
Coronary artery disease 30 (43.5)
Previous CABG 15 (21.7)
Previous PTCA 8 (11.6)
Antiplatelet 36 (56.3)
Aspirin 33 (47.8)
Clopidogrel 1 (1.5)
Aspirin and clopidogrel 4 (5.8)
Smoking history 58 (84.1)
Recenta 32 (46.4)
Previousb 26 (37.7)
Hemodialysis 1 (1.5)
Cerebrovascular disease 9 (13.1)
TIA 4 (5.8)
CVA 5 (7.3)
COPD 12 (17.7)
Untreated 6 (8.8)
Receiving medications 5 (7.4)
Home oxygen therapy 1 (1.5)
Symptomatic aneurysm 8 (11.6)
CABG, Coronary artery bypass graft; COPD, chronic obstructive pulmo-
nary disease; CVA, history of stroke (cerebrovascular accident); eGFR,
estimated glomerular ﬁltration rate; PTCA, percutaneous coronary angio-
plasty or stent; SD, standard deviation; TIA, history of transient ischemic
attack.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
aCurrent smoker or quit <1 year ago.
bQuit smoking >1 year ago.
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symptoms related to the aneurysm were recorded. Renal
function was assessed by serum creatinine (sCr) concentra-
tion and estimated glomerular ﬁltration rate (eGFR) with
the Modiﬁcation of Diet in Renal Disease (MDRD) for-
mula. Renal dysfunction was deﬁned as sCr concentration
>1.5 mg/dL or eGFR <60 mL/min/1.73 m2. Recorded
operative details included retroperitoneal vs transperitoneal
approach; location of proximal aortic anastomosis; location
of cross-clamp relative to renal, superior mesenteric, and
celiac arteries; use of bypass grafts and vessel reimplanta-
tion; lowest intraoperative systolic blood pressure; esti-
mated blood loss; and blood transfusion requirements.
Perioperative outcomes were deﬁned as events occurring
within 30 days of the operation or during the original hos-
pital stay if it was longer than 30 days. Perioperative mor-
tality and morbidity, including myocardial infarction,
pneumonia, arrhythmia, stroke, need for hemodialysis,
paraplegia, bowel ischemia, wound infection, and
unplanned return to the operating room, were tabulated.Primary outcome measures were early and late renal
function, intervention-free survival, and overall survival.
A decrease in renal function was deﬁned as a >30% decline
in eGFR compared with the preoperative value. Late inter-
ventions were deﬁned as any procedure or operative inter-
vention required as a direct result of the original operation,
including incisional hernia and need for anastomotic revi-
sion of the open repair. Statistical analysis was performed
with the SAS 9.2 software (SAS Institute Inc, Cary, NC).
Summary results for continuous variables are reported as
mean 6 standard deviation and as frequency (percentage)
for categorical variables. Wilcoxon rank sum test was used
to assess continuous variables, and c2 or Fisher exact test
was used for categorical variables. Intervention-free survival
and overall survival were calculated by the life-table
method as outlined by the Society for Vascular Surgery
Ad Hoc Committee on Reporting Standards. Univariate
analysis was performed to determine factors that were
signiﬁcantly associated with intervention-free and overall
survival. Multivariate Cox proportional hazards models
were created, if indicated, to assess the association of vari-
ables found signiﬁcant on univariate analysis. A value of
P < .05 was considered signiﬁcant.
RESULTS
During the study period, 211 patients underwent open
AAA repair. Of this cohort, 69 (33%) required a suprarenal
cross-clamp. The mean age of the patients was 71 years,
and 80% of the patients were men (Table I). The majority
were taking a statin (75%), had hypertension (88%), and
had a smoking history (84%). The mean aneurysm size
was 6.12 6 1.5 cm. Twelve percent of patients had symp-
tomatic aneurysms and required urgent repair within
24 hours of admission. Mean preoperative sCr concentra-
tion and mean preoperative eGFR were 1.2 (0.6-5.6)
mg/dL and 66 (10-118) mL/min/1.73 m2, respectively.
Five patients had sCr concentration >1.5 mg/dL, whereas
23 had eGFR <60 mL/min/1.73 m2.
All aortic repairs were performed with an anatomically
placed Dacron graft. The operative approach was retroperi-
toneal in 70%; the location of the aortic cross-clamp was
suprarenal in 54%, supramesenteric in 30%, and supraceliac
in 16%. Fourteen patients had suprarenal aneurysms; the
remainder were juxtarenal. For juxtarenal AAAs, proximal
aortic anastomoses were performed with the suture line
incorporating the lower margin of the renal artery origin.
Aneurysms involving renal/visceral vessels were repaired
by various combinations of beveled anastomoses, vessel
reimplantation, and bypass. Renal/visceral reimplantation
was performed in16patients (23%), and visceral/renal artery
bypass was performed in six patients (9%). No speciﬁc renal
cooling measures were used during the suprarenal cross-
clamping. Mean operative time was 314 minutes; median
operative time was 294 minutes (range, 132-629 minutes).
Mean length of stay was 9 days, with a range of 3 to
41 days. Morbidity occurred in 24 patients (35%) and is
listed in Table II. Six patients required a return to the oper-
ating room for one of the following: lower extremity
Table III. Univariate analysis of factors affecting
perioperative renal function
P value
Age .66
Hypertension .19
Diabetes .08
Hyperlipidemia 1
CAD .55
Preoperative sCr level .8
Preoperative eGFR .6
Statin .5
Antiplatelet 1
Smoker, current or previous 1
Cerebrovascular disease .67
COPD .72
Transperitoneal approach .26
Retroperitoneal approach .26
Aneurysm locationa .53
Concomitant renal artery interventionb .08
Suprarenal cross-clamp .18
Supramesenteric cross-clamp .5
Operative time >4 hours .03
Hypotension
Systolic BP <100 mm Hg .75
Systolic BP <80 mm Hg .33
Estimated blood loss
>1 L .76
>2 L .11
Transfusion .06
Perioperative pneumonia .04
Perioperative arrhythmia .27
Return to operating room .44
BP, Blood pressure; CAD, coronary artery disease, current or history;
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular
ﬁltration rate.
aJuxtarenal vs suprarenal.
bRenal artery bypass, reimplantation.
Table II. Perioperative morbidity
N ¼ 69, No. (%)
Cerebrovascular 0
Paraplegia 1 (1.5)
Myocardial infarction 1 (1.5)
Renal dysfunction 21 (30.4)
Transient insufﬁciency 17 (24.6)
Hemodialysis 4 (5.8)
Perioperative arrhythmia 3 (4.3)
Bowel ischemia requiring resection 2 (2.9)
Return to operating room 8 (11.6)
Pneumonia treatment 7 (10.1)
Wound complications 1 (1.5)
In-hospital mortality 3 (4.35)
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cence, or bleeding. Seven patients required treatment for
pneumonia, which was diagnosed by sputum culture and
conﬁrmed by positive ﬁndings on chest imaging.
Perioperatively, 21 patients (30%) experienced a signif-
icant decline in renal function. Four patients required
hemodialysis. Three of the four patients requiring hemodi-
alysis died in the hospital; in one patient, hemodialysis was
no longer required at time of discharge. Of the 17 patients
with a 30% decline in the eGFR, renal function had
returned to baseline in six by the time of discharge.
Mean discharge sCr concentration was 1.33 (0.4-6.8)
mg/dL, and eGFR was 67 (8-211) mL/min/1.73 m2.
The only perioperative factors signiﬁcantly associated with
renal dysfunction were operative time longer than 4 hours
(P ¼ .03) and pneumonia (P ¼ .04), although requirement
of blood transfusion approached signiﬁcance (Table III).
Preoperative sCr concentration >1.5 mg/dL or eGFR
<60 mL/min/1.73 m2 was not predictive of postoperative
decline in renal function (P ¼ .6).
Three patients died, for a perioperative mortality of 4%.
One patient developed lower extremity and bowel ischemia
resulting in multisystem organ failure. A second patient with
known ischemic cardiomyopathy had a perioperative
myocardial infarction resulting in sustained ventricular
tachycardia and death. A third patient developed hemody-
namic instability andmultisystemorgan failure in thepostop-
erative period. The patient’s family opted to withdraw care.
All three patients required hemodialysis postoperatively.
At a mean follow-up of 3.3 years, reinterventions were
required in eight patients (12%). Indications included
wound complication (3), anastomotic aneurysm/stenosis
(3), incisional hernia (1), and proximal aortic dilation (1).
There were 19 (28%) late deaths, none of which was
directly related to the initial operation.
Forty patients had a documented sCr concentration
and calculated eGFR at follow-up. Seven patients (17.5%)
had a 30% or greater decrease compared with their preop-
erative value, with one patient progressing to hemodialysis.
All seven patients had experienced a perioperative decline
in eGFR of >30%. Whereas preoperative sCr concentration
and eGFR were not associated with decrease in eGFR atfollow-up, both discharge sCr concentration >1.5 mg/dL
(P ¼ .013) and discharge eGFR <60 mL/min/1.73 m2
(P ¼ .022) were associated with a late decline in renal func-
tion (Table IV).
The 5-year intervention-free survival was 62% (Fig 1).
Intervention-free survival was enhanced by antiplatelet use
(P ¼ .04). Prior aortic surgery (P ¼ .06) and new-onset
arrhythmia (P¼ .06) approached signiﬁcance for negatively
affecting intervention-free survival; but onmultivariate anal-
ysis, only antiplatelet use remained signiﬁcant (P < .05;
Table V). Overall 5-year survival and 10-year survival were
77% and 52%, respectively (Fig 2). On univariate analysis,
survival was decreased by a history of pulmonary disease
(P ¼ .003) and perioperative pneumonia (P ¼ .001), both
of which remained signiﬁcant on multivariate analysis
(Table VI). Preoperative renal dysfunction and postopera-
tive decline in renal functionwere not signiﬁcantly associated
with intervention-free or overall survival.
DISCUSSION
Open repair of a juxtarenal or suprarenal AAA requires
the placement of a suprarenal cross-clamp. Warm renal
ischemia time during cross-clamping affects renal function,
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5 6 7
Nb 47              40            25            20             16             11              6
SEa .043           .043           .062            .07           .078            .086         .095
Years 
Fig 1. Intervention-free survival. Error bars show standard error
(SE), which does not exceed 10% for each time interval. N,
Effective sample size.
Table IV. Univariate analysis of factors affecting
long-term renal function
P value
Age .99
Hypertension 1
Diabetes .23
Hyperlipidemia .66
CAD .22
Preoperative eGFR .73
Statin .64
Antiplatelet .43
Smoker, current or previous .28
Cerebrovascular disease .66
COPD .56
Transperitoneal approach .18
Retroperitoneal approach .94
Aneurysm locationa 1
Concomitant renal artery interventionb .39
Operative time > 4 hours .65
Hypotension
Systolic BP <100 mm Hg 1
Systolic BP <80 mm Hg .49
Estimated blood loss
>1 L 1
>2 L 1
Transfusion .39
Perioperative pneumonia 7.2
Perioperative renal dysfunction <.0001
Discharge sCr level, >1.5 mg/dL .01
Discharge eGFR, <60 mL/min/1.73 m2 .02
Perioperative arrhythmia 1
Return to operating room .33
BP, Blood pressure; CAD, coronary artery disease, current or history;
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular
ﬁltration rate.
aJuxtarenal vs suprarenal.
bRenal artery bypass, reimplantation.
Table V. Univariate analysis of factors affecting
intervention-free survival
HR P value
Age 1.05 .1
Race 1.17 .57
Hypertension 0.64 .43
Diabetes 1.12 .54
Hyperlipidemia 0.54 .15
CAD 1.05 .87
Preoperative sCr level 3.19 .34
Preoperative eGFR 1.6 .41
Statin 0.61 .28
Antiplatelet .41 .04
Smoker, current or previous 1.37 .67
Cerebrovascular disease 0.95 .82
COPD 2.42 .09
Prior aortic surgery 3.43 .06
Transperitoneal approach 1.4 .59
Retroperitoneal approach 2.67 .1
Aneurysm locationa 0.61 .47
Concomitant renal artery interventionb 0.6 .12
Hypotension
Systolic BP <100 mm Hg 1.52 .76
Systolic BP <80 mm Hg 1.59 .28
Estimated blood loss
>1 L 0.87 1
>2 L 1.31 .79
Transfusion 1.21 .8
Perioperative pneumonia 3.4 .12
Perioperative reintubation 0.68 .71
Perioperative renal dysfunction 0.4 .23
Perioperative arrhythmia 3.6 .06
Return to operating room 2.3 .19
Renal dysfunction at follow-up 0.68 .46
BP, Blood pressure; CAD, coronary artery disease, current or history;
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular
ﬁltration rate; HR, hazard ratio.
aJuxtarenal vs suprarenal.
bRenal artery bypass, reimplantation.
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has, in some reported experiences, a negative impact on
patient survivaldboth early and late. The impact of a
suprarenal cross-clamp on renal function has been quanti-
ﬁed by Marrocco-Trischitta et al.14 They reported a
median late decrease in eGFR by 31.6% for patients with
suprarenal cross-clamping compared with a median 6.5%
decrease with infrarenal cross-clamping. Tsai et al15
reported a 5-year survival of 74% and found that postoper-
ative renal dysfunction after suprarenal cross-clamping had
a negative impact on survival (relative risk, 1.73; P ¼ .02).
The adverse consequences of a suprarenal cross-clamp on
renal function and survival are currently of interest, given
advances in endovascular technology, which in essence
eliminates the need for a suprarenal cross-clamp during jux-
tarenal or suprarenal repair.
In 69 patients who required a suprarenal cross-clamp,
we found perioperative renal dysfunction and mortality to
be 30% and 4%, respectively. Late renal dysfunction was
documented in 17.5%, with 5-year intervention-free sur-
vival of 62% and overall survival of 77%. Crawford,2 in
1986, reported a perioperative renal dysfunction rate of
16%, perioperative mortality of 7%, and 5-year survival of
75% in 101 patients who underwent a juxtarenal orsuprarenal AAA repair. Other studies report similar results,
although wide variation exists in renal dysfunction
(8%-40%), mortality (<1%-12%), and 5-year survival
Fig 2. Overall survival. Error bars show standard error (SE), which
does not exceed 10% for each time interval. N, Effective sample
size.
Table VI. Univariate analysis of factors affecting survival
HR P value
Age 1.05 .09
Race 0.9 .67
Sex 0.78 .62
Hypertension 1.05 .93
Diabetes 1.19 .91
Hyperlipidemia 1.06 .15
CAD 1.4 .51
Preoperative sCr level 1.2 .86
Preoperative eGFR 1.6 .35
Statin 0.56 .18
Antiplatelet 0.49 .09
Smoker, current or previous 1.3 .67
Cerebrovascular disease 1.4 .54
COPD 3.7 .003
Prior aortic surgery 0.97 .94
Transperitoneal approach 0.4 .1
Retroperitoneal approach 2.59 .1
Aneurysm locationa 1.25 .47
Concomitant renal artery interventionb 0.8 .37
Hypotension
Systolic BP <100 mm Hg 1.04 1
Systolic BP <80 mm Hg 1.6 .28
Estimated blood loss
>1 L 1.22 .77
>2 L 1.23 .79
Transfusion 1.67 .44
Perioperative pneumonia 7.2 .002
Perioperative reintubation 0.9 .84
Perioperative renal dysfunction 1.3 .6
Perioperative arrhythmia 1.84 .27
Return to operating room 2.27 .1
Renal dysfunction at follow-up 0.8 .6
Secondary intervention 1.3 .61
BP, Blood pressure; CAD, coronary artery disease, current or history;
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular
ﬁltration rate; HR, hazard ratio.
aJuxtarenal vs suprarenal.
bRenal artery bypass, reimplantation.
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tarenal and suprarenal AAA repair was higher in earlier
studies compared with infrarenal AAA repair,3 more recent
reports, including our own, document rates that have been
reported for infrarenal AAA repair in prospective random-
ized EVAR trials.1,4,15
A confounding factor in analyzing and comparing renal
dysfunction after suprarenal cross-clamping is that renal
function is deﬁned in disparate ways. To be consistent
with more recent literature and to facilitate comparisons
with current f-EVAR reports, we used percentage change
in eGFR as our primary determinant. The eGFR was calcu-
lated by the MDRD study equation.20 The MDRD for-
mula is known to correlate well with actual changes in
GFR.20-22 Although this and other formulas for estimation
have been shown to be imprecise in certain populations,
they are clearly a more accurate reﬂection of renal function
than sCr concentration alone, particularly in older patients
with some level of preexisting renal dysfunction.
As was true in other reports, a signiﬁcant postoperative
decrease in eGFR was found to be an important factor in
perioperative morbidity and mortality. However, deﬁning
clinical predictors of risk after suprarenal cross-clamping
was elusive. Whereas requirement of any blood transfusion
approached signiﬁcance, increasing transfusion require-
ment, estimated blood loss, and systolic blood pressure
were not signiﬁcant. Pneumonia was found to be signiﬁ-
cant, but the association of early postoperative renal func-
tion decline with transfusion requirement and pneumonia
is not clinically obvious. We surmise that both factors
may be a marker for hemodynamic instability or aortic
reconstruction complexity and associated with a longer
operative time, which was found to have a signiﬁcant
impact on perioperative renal function.
The ﬁnding that preoperative renal function was not a
predictor of early or late postoperative renal dysfunction is
also interesting. This may be due to patient selection bias,which excluded most patients with signiﬁcant preoperative
renal dysfunction and thereby limited the power of statisti-
cal analysis. However, the importance of postoperative
renal dysfunction on late renal function was clearly evident,
with a signiﬁcant late decline in eGFR found only in
patients with postoperative renal dysfunction.
Few late interventions related to the AAA repair were
required, and almost half were unrelated to the aortic
reconstruction. Data in the literature on late intervention-
free survival in open juxtarenal and suprarenal AAA repair
are sparse; the majority of reports provide only the number
or percentage of late complications or do not report on
them at all. By inclusion of all reinterventions (both aortic
and operation related), a more realistic and comparative
assessment is given of intervention-free survival in the
current endovascular environment.23 The reason for the
intervention-free survival beneﬁt in patients receiving anti-
platelet agents is unclear. However, because it did not
affect overall survival, it may be an indicator of a positive
effect on the durability of the aortic reconstruction. Further
study will be required to answer if this is so.
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vious studies.1-3,15,16 It is well known that after aortic
reconstruction, late survival is negatively affected by exist-
ing pulmonary disease, and our experience is no excep-
tion.24-28 Chong et al1 speciﬁcally looked at 5-year
survival in patients requiring suprarenal cross-clamping
and demonstrated that chronic obstructive pulmonary dis-
ease signiﬁcantly decreased late survival. Surprisingly, we
found late survival to not be inﬂuenced by preoperative,
perioperative, or postoperative renal dysfunction.
Whereas our study speciﬁcally addresses open repair of
juxtarenal and suprarenal AAAs, the current interest is its
comparative effectiveness to f-EVAR. f-EVAR carries a
risk of renal dysfunction, and that along with the need
for reintervention remains a primary concern in both early
and late outcomes.7-13 A study by Kristmundsson29
reported a 30-day mortality of 3.7% and perioperative renal
dysfunction (deﬁned as >30% rise in sCr concentration) in
35% of patients. Late renal function persisted in 16% at a
mean follow-up of 25 months. A more recent report
from the same patient cohort with a mean follow-up of
5.5 years found that 26% of patients with normal preoper-
ative renal function and 22% of patients with preoperative
renal dysfunction developed a >30% change in eGFR.30
The 5-year intervention-free survival was 56%, and overall
5-year survival was 60%. In a recent review of eight studies
on f-EVAR, average 30-day mortality was 1.7% (range,
0%-3.7%), renal dysfunction 11.4% (range, 0%-35%),
hemodialysis requirement 1.9% (range, 0%-11.1%), and
late mortality 15.1%, with a mean follow-up of 19.1 months
(range, 0-87 months).31
CONCLUSIONS
Direct comparison of our study and others with the
early results of f-EVAR is not possible, but this study
and the collective literature provide guidance for applica-
tion of f-EVAR absent a direct comparison through pro-
spective randomized trials. Our ﬁndings indicate that
about a quarter of patients who require a suprarenal
cross-clamp during open juxtarenal or suprarenal AAA
repair will experience renal dysfunction. However,
although perioperative renal dysfunction is frequent, it
has limited impact on intervention-free and overall
patient survival. Intervention-free survival and overall sur-
vival are reasonable, given the comorbidities of this
patient population, with pre-existing pulmonary disease
being the main driver of late mortality. These ﬁndings
provide additional guidance for patient selection in the
fenestrated/branched graft era.
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